AstraZeneca's Monalizumab and Oleclumab Injections Granted Clinical Trial Approval in China for Unresectable Stage III NSCLC

On March 17, 2022, the CDE website announced that AstraZeneca's Monalizumab for injection and Oleclumab Injection have been approved for clinical trials. Both drugs are indicated for combination therapy with durvalumab to treat patients with locally advanced (Stage III), unresectable non-small cell lung cancer (NSCLC) who have not progressed following radical platinum-based concurrent chemoradiotherapy.